Neurocrine biosciences presents new post-hoc analysis: treatment with ingrezza® (valbenazine) capsules achieves earlier remission of tardive dyskinesia symptoms while reducing patient-reported disease burden

The kinect-pro™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. post-hoc analysis from kinect-pro demonstrated substantial symptomatic remission rates at week 24, even earlier than previous studies have reported.
NBIX Ratings Summary
NBIX Quant Ranking